Thank you for joining us today.
Over the course of the last three meetings, we have met with organizations and departmental officials all of whom are connected in some way with the study under way on post-marketing surveillance of pharmaceutical products.
First of all, I wonder what proportion of their budget and how much time each organization spends on post-marketing surveillance of pharmaceutical products?
Secondly, I am curious as to how all of the organizations responsible for post-marketing surveillance of pharmaceutical products work together and how information is shared? What happens when an agency receives information that could require more in-depth studies on its pharmaceutical products and their effects?